Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Allergan
Single-center, multiple-dose study evaluting the local pharmacokinetics and tolerability of bimatoprost following 14 days of once daily topical administration of bimatoprost Formulation A and Formulation B (both containing 1% bimatoprost) to the scalp of male patients With androgenetic alopecia
Age
18–49
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Patients with mild to moderate Androgenetic Alopecia of the vertex area of the scalp.
You may not be if
Patients with uncontrolled systemic disease
History of significant cardiovascular disease
Scarring disease, infection, or abnormality of the scalp or hair shaft or systemic disease that could cause temporary hair loss (eg, seborrheic dermatitis, psoriatic dermatitis, alopecia areata, cicatricial alopecia, uncontrolled hyperthyroidism/hypothyroidism, tinea infections, and genetic disorders)
Patients who have received hair transplants or have had scalp reductions
Abnormal bone biomarker laboratory results.
Clareo Health | Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia
